Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CHRNA1 | P02708 | 2/20 | 0.33 |
| ▸ | CHRNG | P07510 | 2/20 | 0.33 |
| ▸ | CHRNB1 | P11230 | 2/20 | 0.33 |
| ▸ | CHRND | Q07001 | 2/20 | 0.33 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.33 |
| ▸ | CCKBR | P32239 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.32 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.32 |
| ▸ | TLR2 | O60603 | 3/20 | 0.32 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22566705 | 0.90 | GLP1R (0.46) | GLP1RMEN1KMT2ACHRNA1CHRNG | |
| SCHEMBL21287290 | 0.85 | GLP1R (0.42) | GLP1RTLR2 | |
| SCHEMBL20800942 | 0.85 | GLP1R (0.42) | GLP1RTLR2 | |
| SCHEMBL24697694 | 0.85 | GLP1R (0.41) | GLP1RMEN1KMT2ACCKBRTLR2 | |
| SCHEMBL21287666 | 0.84 | GLP1R (0.41) | GLP1RTLR2 | |
| SCHEMBL20800989 | 0.84 | GLP1R (0.41) | GLP1RTLR2 | |
| SCHEMBL24697314 | 0.84 | GLP1R (0.40) | GLP1RCCKBR | |
| SCHEMBL20375511 | 0.84 | GLP1R (0.41) | GLP1RTLR2 | |
| SCHEMBL21393232 | 0.83 | GLP1R (0.40) | GLP1RMEN1KMT2ATLR2 | |
| SCHEMBL20375520 | 0.83 | GLP1R (0.40) | GLP1RTLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230323350-A1 | RNAi Agents And Compositions for Inhibiting Expression of Apolipoprotein C-III (APOC3) | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2023-10-12 | — | — | US | disclosed |
| US-20220056454-A1 | RNAi Agents for Inhibiting Expression of 17beta-HSD Type 13 (HSD17B13), Compositions Thereof, and Methods of Use | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2022-02-24 | — | — | US | disclosed |
| US-11214801-B2 | RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3) | Arrowhead Pharmaceuticals, Inc. (US) | 2022-01-04 | — | — | US | disclosed |
| US-20210403908-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF HEPATITIS D VIRUS INFECTION | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED (GB) | 2021-12-30 | — | — | US | disclosed |
| US-20210395745-A1 | RNAI AGENTS FOR HEPATITIS B VIRUS INFECTION | Arrowhead Pharmaceuticals, Inc. (US) | 2021-12-23 | — | — | US | disclosed |
| US-11203756-B2 | Alpha-1 antitrypsin (AAT) RNAi agents, compositions including AAT RNAi agents, and methods of use | Arrowhead Pharmaceuticals, Inc. (US) | 2021-12-21 | — | — | US | disclosed |
| US-20210285000-A1 | COMBINATION THERAPY FOR TREATING HEPATITIS B VIRUS INFECTION | Janssen Pharmaceuticals, Inc. | 2021-09-16 | — | — | US | disclosed |
| US-20210238602-A1 | RNAi Agents And Compositions for Inhibiting Expression of Angiopoietin-Like 3 (ANGPTL3), And Methods Of Use | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2021-08-05 | — | — | US | disclosed |
| US-20200330499-A1 | COMBINATION THERAPY FOR TREATING HEPATITIS B VIRUS INFECTION | Janssen Pharmaceuticals, Inc. (US) | 2020-10-22 | — | — | US | disclosed |
| US-20200299690-A1 | RNAi Agents And Compositions for Inhibiting Expression of Apolipoprotein C-III (APOC3) | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2020-09-24 | — | — | US | disclosed |
| US-20200263179-A1 | COMPOSITIONS AND METHODS FOR INHIBITING GENE EXPRESSION OF LPA | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2020-08-20 | — | — | US | disclosed |
| US-20200208149-A1 | Alpha-1 AntiTrypsin (AAT) RNAi Agents, Compositions Including AAT RNAi Agents, And Methods of Use | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2020-07-02 | — | — | US | disclosed |
| US-10597657-B2 | RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3) | Arrowhead Pharmaceuticals, Inc. (US) | 2020-03-24 | — | — | US | disclosed |
| US-20190078088-A1 | RNAi Agents And Compositions for Inhibiting Expression of Apolipoprotein C-III (APOC3) | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2019-03-14 | — | — | US | disclosed |
| US-9932586-B2 | Compositions and methods for inhibiting gene expression of LPA | Arrowhead Pharmaceuticals, Inc. (US) | 2018-04-03 | — | — | US | disclosed |
| US-20170096665-A1 | Compositions and Methods for Inhibiting Gene Expression of LPA | Arrowhead Pharmaceuticals, Inc. | 2017-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200208149-A1 | Alpha-1 AntiTrypsin (AAT) RNAi Agents, Compositions Including AAT RNAi Agents, And Methods of Use | SERPINA2, SERPINC1, SERPINA3 | GLP1R 4004/4885MEN1 1361/4885KMT2A 3675/4885 |
| US-20220056454-A1 | RNAi Agents for Inhibiting Expression of 17beta-HSD Type 13 (HSD17B13), Compositions Thereof, and Methods of Use | HSD17B13, HSD17B3, HSD17B10 | GLP1R 3037/4885MEN1 4798/4885KMT2A 3559/4885 |
| US-11203756-B2 | Alpha-1 antitrypsin (AAT) RNAi agents, compositions including AAT RNAi agents, and methods of use | SERPINA2, SERPINC1, SERPINA3 | GLP1R 4004/4885MEN1 1361/4885KMT2A 3675/4885 |
| US-11214801-B2 | RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3) | APOB, LDLR, APOL1 | GLP1R 2229/4885MEN1 4419/4885KMT2A 3584/4885 |
| US-20190078088-A1 | RNAi Agents And Compositions for Inhibiting Expression of Apolipoprotein C-III (APOC3) | APOB, LDLR, APOL1 | GLP1R 2229/4885MEN1 4419/4885KMT2A 3584/4885 |
| US-10597657-B2 | RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3) | APOB, LDLR, APOL1 | GLP1R 2229/4885MEN1 4419/4885KMT2A 3584/4885 |
| US-20210285000-A1 | COMBINATION THERAPY FOR TREATING HEPATITIS B VIRUS INFECTION | HAVCR2, EIF2AK2, IFNAR1 | GLP1R 4338/4885MEN1 4846/4885KMT2A 3186/4885 |
| US-20200299690-A1 | RNAi Agents And Compositions for Inhibiting Expression of Apolipoprotein C-III (APOC3) | APOB, LDLR, APOL1 | GLP1R 2229/4885MEN1 4419/4885KMT2A 3584/4885 |
| US-20210395745-A1 | RNAI AGENTS FOR HEPATITIS B VIRUS INFECTION | HAVCR2, ASGR1, NR1H4 | GLP1R 3941/4885MEN1 3908/4885KMT2A 2074/4885 |
| US-20210403908-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF HEPATITIS D VIRUS INFECTION | HAVCR2, EIF2AK2, HDGF | GLP1R 4794/4885MEN1 4687/4885KMT2A 3071/4885 |
| US-20200330499-A1 | COMBINATION THERAPY FOR TREATING HEPATITIS B VIRUS INFECTION | HAVCR2, HCCS, EIF2AK2 | GLP1R 4386/4885MEN1 4684/4885KMT2A 2708/4885 |
| US-20230323350-A1 | RNAi Agents And Compositions for Inhibiting Expression of Apolipoprotein C-III (APOC3) | APOB, LDLR, APOL1 | GLP1R 2229/4885MEN1 4419/4885KMT2A 3584/4885 |
| US-20210238602-A1 | RNAi Agents And Compositions for Inhibiting Expression of Angiopoietin-Like 3 (ANGPTL3), And Methods Of Use | TEK, PLIN3, PNLIP | GLP1R 459/4885MEN1 2902/4885KMT2A 2388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.